Journal article
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
Abstract
BACKGROUND: Patients receiving chemotherapy for cancer are at increased risk for venous thromboembolism. Limited data support the clinical benefit of antithrombotic prophylaxis.
METHODS: In this double-blind, multicenter trial, we evaluated the efficacy and safety of the ultra-low-molecular-weight heparin semuloparin for prevention of venous thromboembolism in patients receiving chemotherapy for cancer. Patients with metastatic or locally …
Authors
Agnelli G; George DJ; Kakkar AK; Fisher W; Lassen MR; Mismetti P; Mouret P; Chaudhari U; Lawson F; Turpie AGG
Journal
New England Journal of Medicine, Vol. 366, No. 7, pp. 601–609
Publisher
Massachusetts Medical Society
Publication Date
February 16, 2012
DOI
10.1056/nejmoa1108898
ISSN
0028-4793